| Literature DB >> 35630985 |
Guillermo Aragoneses-Cazorla1, M Pilar Buendia-Nacarino1, Maria L Mena1, Jose L Luque-Garcia1.
Abstract
Silver nanoparticles (AgNPs) are currently used in many different industrial, commercial and health fields, mainly due to their antibacterial properties. Due to this widespread use, humans and the environment are increasingly exposed to these types of nanoparticles, which is the reason why the evaluation of the potential toxicity associated with AgNPs is of great importance. Although some of the toxic effects induced by AgNPs have already been shown, the elucidation of more complete mechanisms is yet to be achieved. In this sense, and since the integration of metabolomics and transcriptomics approaches constitutes a very useful strategy, in the present study targeted and untargeted metabolomics and DNA microarrays assays have been combined to evaluate the molecular mechanisms involved in the toxicity induced by 10 nm AgNPs. The results have shown that AgNPs induce the synthesis of glutathione as a cellular defense mechanism to face the oxidative environment, while inducing the depletion of relevant molecules implicated in the synthesis of important antioxidants. In addition, it has been observed that AgNPs completely impair the intracellular energetic metabolism, especially affecting the production of adenosine triphosphate (ATP) and disrupting the tricarboxylic acids cycle. It has been demonstrated that AgNPs exposure also affects the glycolysis pathway. The effect on such pathway differs depending on the step of the cycle, which a significant increase in the levels of glucose as way to counterbalance the depleted levels of ATP.Entities:
Keywords: metabolic pathways; metabolomics; oxidative stress; silver nanoparticles; toxicity mechanisms; transcriptomics
Year: 2022 PMID: 35630985 PMCID: PMC9146515 DOI: 10.3390/nano12101762
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Figure 1Characterization of the AgNPs: (A) TEM Micrographs; (B) Hydrodynamic size distribution; (C) ζ–potential.
Figure 2Cytotoxicity of AgNPs: (A) MTT-based cell viability assay; (B) Trypan blue-based cell death assay.
Figure 3Intracellular levels of ATP, ADP, NADH and NAD+ metabolites in HepG2 cells after exposure to 5 µg/mL of 10 nm AgNPs for 72 h. Data were analyzed by ANOVA followed by Bonferroni’s multiple-comparison test. Statistical significance: ** p < 0.005. *** p < 0.001.
Figure 4PCA results from the untargeted metabolomics experiment. (A) 2D scores plot of the first principal component (PC1) versus the second principal component (PC2) for control (n = 5) (red area) and cells treated with 5 μg/mL of AgNPs for 72 h (n = 5) (green area). (B) Loadings plot of PC1 versus PC2 for the 28 quantified metabolites (the number of each metabolite correlates with the identified metabolites as shown in Supplemental Table S2).
Altered metabolites found in HepG2 cells exposed to 5 μg/mL of AgNPs for 72 h by the GC-MS-based untargeted metabolomics approach (95% confidence level).
| Metabolite Name | Retention Time (min) | NIST Rmatch | RM |
|---|---|---|---|
| Glutamine | 19.890 | 874 | 0.69 |
| Threitol | 17.864 | 851 | 0.62 |
| Xylofuranose | 32.638 | 793 | 0.48 |
| L-Cysteine | 18.711 | 868 | 0.33 |
| D-Glucose | 24.964 | 870 | 0.31 |
| L-Threonine | 15.285 | 865 | 0.30 |
| L-Proline | 18.014 | 881 | 0.25 |
| L-Aspartic acid | 18.086 | 791 | 0.24 |
| D-Fructose | 24.294 | 767 | 0.23 |
| β-D-Glucopyranose | 26.375 | 890 | 0.15 |
| D-Galactose | 25.192 | 848 | 0.15 |
| Pantothenic acid | 26.473 | 887 | 0.13 |
| Malic acid | 17.466 | 728 | 0.13 |
| Rythonic acid | 18.541 | 767 | 0.12 |
| Myo-inositol | 27.874 | 830 | 0.10 |
| Octadecanoic acid | 30.225 | 839 | 0.09 |
| Myo-inositol phosphate | 32.426 | 827 | 0.07 |
| L-Tyrosine | 25.543 | 782 | 0.06 |
| Phosphoric acid | 22.634 | 868 | 0.05 |
| L-Leucine | 19.177 | 700 | 0.03 |
Figure 5Illustration of the main metabolic reactions and pathways where the main impaired amino acids and TCA cycle intermediates found after AgNPs exposure take part.
Figure 6Scheme of the glycolysis pathway and the transcripts controlling its progression.
Altered transcripts found in HepG2 cells exposed to 5 μg/mL of AgNPs for 72 h by the transcriptome approach.
| Gene Name | Gene Code | FC |
|---|---|---|
| Phosphofructokinase, platelet | PFKP | 33.45 |
| Hexokinase 1 | HK1 | 11.86 |
| 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 | PFKFB1 | 4.62 |
| Glutamate-cysteine ligase, catalytic subunit | GCLC | 3.49 |
| Enolase 2 (gamma, neuronal) | ENO2 | 2.90 |
| Solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 | SLC7A11 | 2.66 |
| Glutathione synthetase | GSS | 2.16 |
| Myo-inositol oxygenase | MIOX | 2.08 |
| Solute carrier family 2 (facilitated glucose transporter), member 3 | SLC2A3 | 2.07 |
| Glutaminase | GLS1 | 0.98 |
| Glutaminase 2 (liver, mitochondrial) | GLS2 | 0.92 |
| Cystathionine gamma-lyase | CTH | 0.70 |
| Triosephosphate isomerase 1 | TPI1 | 0.47 |
| Phosphoglucomutase 3 | PGM3 | 0.45 |
| Inositol-3-phosphate synthase 1 | INO1 | 0.43 |
| Pantothenate kinase 3 | PANK3 | 0.42 |
| Fumarate hydratase | FH | 0.41 |
| Isocitrate dehydrogenase 2 (NADP+), mitochondrial | IDH2 | 0.41 |
| Phosphofructokinase, liver | PFKL | 0.40 |
| Cystathionine-beta-synthase | CBS | 0.37 |
| Glutamate-ammonia ligase | GLUL | 0.36 |
| Hexokinase 2 | HK2 | 0.36 |
| Prolyl 4-hydroxylase, alpha polypeptide I | P4HA1 | 0.35 |
| Inositol(myo)-1(or 4)-monophosphatase 2 | IMPA2 | 0.33 |
| Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 | SLC7A2 | 0.28 |
| Pyrroline-5-carboxylate reductase 1 | PYCR1 | 0.28 |
| Fatty acid synthase | FASN | 0.27 |
| Isocitrate dehydrogenase 1 (NADP+) | IDH1 | 0.23 |
| Solute carrier family 2 (facilitated glucose transporter), member 2 | SLC2A2 | 0.23 |
| Pyruvate kinase, liver and RBC | PKLR | 0.18 |
| Glutamate dehydrogenase 1 | GLUD1 | 0.17 |
| Glutamate dehydrogenase 2 | GLUD2 | 0.17 |
| Phosphoglucomutase 1 | PGM1 | 0.14 |
| Aldolase C, fructose-bisphosphate | ALDOC | 0.13 |
| Argininosuccinate synthase 1 | ASS1 | 0.12 |
| Aldehyde dehydrogenase 18 family, member A1 | ALDH18A1 | 0.12 |
| Glutamic pyruvate transaminase (alanine aminotransferase) 2 | GPT2 | 0.11 |
| Pantothenate kinase 1 | PANK1 | 0.11 |
| 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4; microRNA 6823 | PFKFB4 | 0.10 |
| Glucose-6-phosphatase, catalytic subunit | G6PC | 0.02 |